{
  "run": {
    "id": "cmnr14uxp05tcp658778h4dms",
    "region": "US",
    "assetId": "cmnr14uxd05t8p6584ckcdyc0",
    "ticker": "PODD",
    "snapshotId": "cmnr14uxj05tap658c2uwk7z8",
    "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux",
    "createdAt": "2026-04-09T05:21:36.922Z",
    "promptTemplate": {
      "id": "cmnqt07si0005lm3jzpxuu1ux",
      "name": "Oficial 08.apr.2026",
      "version": 1
    },
    "snapshot": {
      "id": "cmnr14uxj05tap658c2uwk7z8",
      "assetId": "cmnr14uxd05t8p6584ckcdyc0",
      "asOf": "2026-04-08T20:00:01.000Z",
      "snapshot": {
        "asOf": "2026-04-08T20:00:01.000Z",
        "quote": {
          "asOf": "2026-04-08T20:00:01.000Z",
          "open": null,
          "price": 203.51,
          "dayLow": 201.995,
          "volume": 687303,
          "dayHigh": 209,
          "currency": "USD",
          "prevClose": 202.46,
          "week52Low": 201.995,
          "week52High": 354.88
        },
        "fundamentals": {
          "pe": 4205.57142857143,
          "beta": 0.978708060123539,
          "epsTTM": 0.07,
          "fcfTTM": -7600000,
          "growth": {
            "epsYoy": -0.4120603015075377,
            "revenueYoy": 0.3072504344468044
          },
          "sector": "Surgical & Medical Instruments & Apparatus",
          "margins": {
            "net": 0.09124478416602046,
            "gross": 0.7163324840293933,
            "operating": 0.1749566116465419
          },
          "website": null,
          "industry": null,
          "pegRatio": -58.4107142857143,
          "ebitdaTTM": 109800000,
          "forwardPe": 210.278571428571,
          "marketCap": 22100000000,
          "totalCash": 716100000,
          "totalDebt": 949200000,
          "debtEquity": 3.00020990764064,
          "quickRatio": 1.812968681076312,
          "revenueTTM": 2708100000,
          "companyName": "INSULET CORP",
          "priceToBook": 42.8700802896725,
          "currentRatio": 2.814292015880018,
          "dividendYield": null,
          "returnOnAssets": 0.07745110330992978,
          "returnOnEquity": 0.00965575146935348,
          "analystOpinions": null,
          "businessSummary": null,
          "enterpriseValue": 21177906250,
          "analystTargetLow": null,
          "analystTargetHigh": null,
          "analystTargetMean": null,
          "fullTimeEmployees": null,
          "sharesOutstanding": 70395848,
          "enterpriseToEbitda": 192.8771061020036,
          "analystTargetMedian": null,
          "enterpriseToRevenue": 7.820208356412245,
          "operatingCashflowTTM": 569300000,
          "analystRecommendationKey": null
        }
      },
      "createdAt": "2026-04-09T05:21:36.919Z"
    },
    "results": [
      {
        "id": "cmnr14uxr05tep658vecp7fn9",
        "runId": "cmnr14uxp05tcp658778h4dms",
        "modelId": "anthropic",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:01.000Z\",\"ticker\":\"PODD\",\"currency\":\"USD\",\"current_price\":203.51,\"target_price_6m\":218,\"target_price_12m\":235,\"recommendation\":\"BUY\",\"confidence\":0.55,\"thesis_bullets\":[\"Revenue growing 30% YoY but EPS declined 41%, margin execution key\",\"Stock near 52-week low; ~43% drawdown may overshoot to downside\",\"Omnipod 5 global rollout sustains strong top-line momentum\",\"Gross margin of 71.6% supports long-term earnings power potential\",\"High EV/Revenue of 7.8x limits margin of safety at current levels\"],\"key_drivers\":[{\"driver\":\"Omnipod 5 global adoption and new patient starts\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Gross margin stability above 70%\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Operating leverage as scale improves on fixed cost base\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Growing international revenue contribution\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Tariff and trade policy risk on device manufacturing\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"EPS decline despite revenue growth signals cost pressure\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Negative FCF TTM raises capital allocation concerns\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Debt/equity of 3.0x limits financial flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Tariff escalation materially impacts COGS and device pricing\",\"Competitive insulin pump launches erode Omnipod market share\",\"Failure to convert revenue growth into positive free cash flow\",\"GLP-1 weight-loss drugs reduce addressable Type 2 diabetes market\",\"Multiple compression in growth med-tech if macro deteriorates\",\"Regulatory or reimbursement changes in key international markets\"],\"assumptions\":{\"revenue_cagr_3y\":0.18,\"ebit_margin_target\":0.22,\"wacc\":0.10,\"terminal_multiple\":7.0},\"scenarios\":{\"bear\":{\"target_price\":165,\"prob\":0.20,\"notes\":\"Tariff impact + competition compress multiples to 5x fwd EV/Rev.\"},\"base\":{\"target_price\":235,\"prob\":0.55,\"notes\":\"Steady 18-20% revenue growth, modest margin expansion, 6.5x fwd EV/Rev.\"},\"bull\":{\"target_price\":305,\"prob\":0.25,\"notes\":\"Accelerating adoption, margin inflection, re-rating toward 8x fwd EV/Rev.\"}},\"method_notes\":\"Forward EV/Revenue anchor on ~$3.25B estimated NTM revenue. Base assigns 6.5x multiple reflecting growth deceleration and macro risk. 12M target of $235 implies ~15% upside, consistent with BUY. Confidence held at 0.55 due to mixed signals: strong top-line growth offset by EPS decline, negative FCF, and elevated leverage. Sell-side targets noted but not used as numeric inputs. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:01.000Z",
          "model": "ai-equity-research-v1",
          "risks": [
            "Tariff escalation materially impacts COGS and device pricing",
            "Competitive insulin pump launches erode Omnipod market share",
            "Failure to convert revenue growth into positive free cash flow",
            "GLP-1 weight-loss drugs reduce addressable Type 2 diabetes market",
            "Multiple compression in growth med-tech if macro deteriorates",
            "Regulatory or reimbursement changes in key international markets"
          ],
          "ticker": "PODD",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.55,
              "notes": "Steady 18-20% revenue growth, modest margin expansion, 6.5x fwd EV/Rev.",
              "target_price": 235
            },
            "bear": {
              "prob": 0.2,
              "notes": "Tariff impact + competition compress multiples to 5x fwd EV/Rev.",
              "target_price": 165
            },
            "bull": {
              "prob": 0.25,
              "notes": "Accelerating adoption, margin inflection, re-rating toward 8x fwd EV/Rev.",
              "target_price": 305
            }
          },
          "confidence": 0.55,
          "assumptions": {
            "wacc": 0.1,
            "revenue_cagr_3y": 0.18,
            "terminal_multiple": 7,
            "ebit_margin_target": 0.22
          },
          "key_drivers": [
            {
              "driver": "Omnipod 5 global adoption and new patient starts",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Gross margin stability above 70%",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Operating leverage as scale improves on fixed cost base",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Growing international revenue contribution",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Tariff and trade policy risk on device manufacturing",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "EPS decline despite revenue growth signals cost pressure",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Negative FCF TTM raises capital allocation concerns",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Debt/equity of 3.0x limits financial flexibility",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Forward EV/Revenue anchor on ~$3.25B estimated NTM revenue. Base assigns 6.5x multiple reflecting growth deceleration and macro risk. 12M target of $235 implies ~15% upside, consistent with BUY. Confidence held at 0.55 due to mixed signals: strong top-line growth offset by EPS decline, negative FCF, and elevated leverage. Sell-side targets noted but not used as numeric inputs. Not investment advice.",
          "current_price": 203.51,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Revenue growing 30% YoY but EPS declined 41%, margin execution key",
            "Stock near 52-week low; ~43% drawdown may overshoot to downside",
            "Omnipod 5 global rollout sustains strong top-line momentum",
            "Gross margin of 71.6% supports long-term earnings power potential",
            "High EV/Revenue of 7.8x limits margin of safety at current levels"
          ],
          "target_price_6m": 218,
          "target_price_12m": 235
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "anthropic",
            "webSearch": {
              "enabled": false,
              "maxToolCalls": 2,
              "disabledReason": null
            },
            "pauseTurns": 0,
            "stopReason": "end_turn"
          },
          "sanityIssues": []
        },
        "latencyMs": 45868,
        "createdAt": "2026-04-09T05:21:36.922Z",
        "usage": {
          "inputTokens": 3495,
          "outputTokens": 2074,
          "costUsd": 0.069325
        }
      },
      {
        "id": "cmnr14uxr05thp65810k5v9wq",
        "runId": "cmnr14uxp05tcp658778h4dms",
        "modelId": "deepseek.reasoner",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"Proprietary DCF Model\",\n  \"as_of\": \"2026-04-08T20:00:01.000Z\",\n  \"ticker\": \"PODD\",\n  \"currency\": \"USD\",\n  \"current_price\": 203.51,\n  \"target_price_6m\": 210.0,\n  \"target_price_12m\": 220.0,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.65,\n  \"thesis_bullets\": [\"Revenue growth exceeding 20% annually.\", \"Margin expansion potential from operational leverage.\", \"High leverage constrains financial flexibility.\", \"Intense competition in insulin delivery market.\", \"Valuation discounts future profitability improvements.\"],\n  \"key_drivers\": [\n    {\"driver\": \"Revenue growth from new products\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n    {\"driver\": \"Operating margin improvement\", \"impact\": \"MED\", \"direction\": \"POS\"},\n    {\"driver\": \"Debt reduction efforts\", \"impact\": \"MED\", \"direction\": \"POS\"},\n    {\"driver\": \"Regulatory approvals\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n    {\"driver\": \"Competition intensity\", \"impact\": \"HIGH\", \"direction\": \"NEG\"},\n    {\"driver\": \"Reimbursement changes\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n    {\"driver\": \"Economic conditions\", \"impact\": \"LOW\", \"direction\": \"NEG\"},\n    {\"driver\": \"Innovation pipeline\", \"impact\": \"HIGH\", \"direction\": \"POS\"}\n  ],\n  \"risks\": [\"Regulatory setbacks\", \"Increased competition\", \"Execution missteps\", \"Macroeconomic downturn\", \"Supply chain disruptions\"],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.20,\n    \"ebit_margin_target\": 0.20,\n    \"wacc\": 0.09,\n    \"terminal_multiple\": 20.0\n  },\n  \"scenarios\": {\n    \"bear\": {\"target_price\": 180.0, \"prob\": 0.2, \"notes\": \"Slower growth and margin pressure.\"},\n    \"base\": {\"target_price\": 220.0, \"prob\": 0.6, \"notes\": \"Steady execution on growth plans.\"},\n    \"bull\": {\"target_price\": 250.0, \"prob\": 0.2, \"notes\": \"Faster adoption and cost savings.\"}\n  },\n  \"method_notes\": \"Valuation based on DCF with assumed 20% revenue CAGR and 20% EBIT margin. 12M target implies 8% upside. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:01.000Z",
          "model": "Proprietary DCF Model",
          "risks": [
            "Regulatory setbacks",
            "Increased competition",
            "Execution missteps",
            "Macroeconomic downturn",
            "Supply chain disruptions"
          ],
          "ticker": "PODD",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Steady execution on growth plans.",
              "target_price": 220
            },
            "bear": {
              "prob": 0.2,
              "notes": "Slower growth and margin pressure.",
              "target_price": 180
            },
            "bull": {
              "prob": 0.2,
              "notes": "Faster adoption and cost savings.",
              "target_price": 250
            }
          },
          "confidence": 0.65,
          "assumptions": {
            "wacc": 0.09,
            "revenue_cagr_3y": 0.2,
            "terminal_multiple": 20,
            "ebit_margin_target": 0.2
          },
          "key_drivers": [
            {
              "driver": "Revenue growth from new products",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Operating margin improvement",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Debt reduction efforts",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Regulatory approvals",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Competition intensity",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Reimbursement changes",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Economic conditions",
              "impact": "LOW",
              "direction": "NEG"
            },
            {
              "driver": "Innovation pipeline",
              "impact": "HIGH",
              "direction": "POS"
            }
          ],
          "method_notes": "Valuation based on DCF with assumed 20% revenue CAGR and 20% EBIT margin. 12M target implies 8% upside. Not investment advice.",
          "current_price": 203.51,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Revenue growth exceeding 20% annually.",
            "Margin expansion potential from operational leverage.",
            "High leverage constrains financial flexibility.",
            "Intense competition in insulin delivery market.",
            "Valuation discounts future profitability improvements."
          ],
          "target_price_6m": 210,
          "target_price_12m": 220
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "endpoint": "https://api.deepseek.com/v1/chat/completions",
            "provider": "deepseek",
            "webSearch": {
              "enabled": false,
              "supported": false
            },
            "responseFormat": "json_object"
          },
          "sanityIssues": []
        },
        "latencyMs": 366,
        "createdAt": "2026-04-09T05:21:36.922Z",
        "usage": {
          "inputTokens": 2015,
          "outputTokens": 3848,
          "costUsd": 0.00218
        }
      },
      {
        "id": "cmnr14uxr05tfp6588l3o36lo",
        "runId": "cmnr14uxp05tcp658778h4dms",
        "modelId": "gemini.3-pro",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"Equity Research Analyst Model\",\"as_of\":\"2026-04-08T20:00:01.000Z\",\"ticker\":\"PODD\",\"currency\":\"USD\",\"current_price\":203.51,\"target_price_6m\":218.0,\"target_price_12m\":235.0,\"recommendation\":\"BUY\",\"confidence\":0.65,\"thesis_bullets\":[\"Omnipod 5 is the only tubeless AID system, offering a unique competitive advantage.\",\"Massive untapped market in Type 2 diabetes patients currently using MDI therapy.\",\"GLP-1 impact is likely overstated; data shows increased pump adoption among users.\",\"Strong gross margins provide significant operating leverage as the business scales.\",\"International expansion and pharmacy channel access drive sustainable 20%+ revenue growth.\"],\"key_drivers\":[{\"driver\":\"Omnipod 5 adoption\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Type 2 market penetration\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"International rollout\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"GLP-1 drug sentiment\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Competitive pricing\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Pharmacy channel expansion\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"R&D pipeline\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Increased competition from Tandem and Medtronic.\",\"Adverse long-term GLP-1 clinical data.\",\"Supply chain disruptions for electronic components.\",\"Regulatory delays for new product indications.\"],\"assumptions\":{\"revenue_cagr_3y\":0.22,\"ebit_margin_target\":0.20,\"wacc\":0.095,\"terminal_multiple\":35.0},\"scenarios\":{\"bear\":{\"target_price\":165.0,\"prob\":0.2,\"notes\":\"Increased competition and GLP-1 adoption slows pump growth.\"},\"base\":{\"target_price\":235.0,\"prob\":0.6,\"notes\":\"Steady Omnipod 5 adoption and successful Type 2 expansion.\"},\"bull\":{\"target_price\":285.0,\"prob\":0.2,\"notes\":\"Rapid international growth and faster-than-expected Type 2 penetration.\"}},\"method_notes\":\"Valuation based on 10-year DCF and forward EV/EBITDA. Recommendation reflects 15% upside. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:01.000Z",
          "model": "Equity Research Analyst Model",
          "risks": [
            "Increased competition from Tandem and Medtronic.",
            "Adverse long-term GLP-1 clinical data.",
            "Supply chain disruptions for electronic components.",
            "Regulatory delays for new product indications."
          ],
          "ticker": "PODD",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Steady Omnipod 5 adoption and successful Type 2 expansion.",
              "target_price": 235
            },
            "bear": {
              "prob": 0.2,
              "notes": "Increased competition and GLP-1 adoption slows pump growth.",
              "target_price": 165
            },
            "bull": {
              "prob": 0.2,
              "notes": "Rapid international growth and faster-than-expected Type 2 penetration.",
              "target_price": 285
            }
          },
          "confidence": 0.65,
          "assumptions": {
            "wacc": 0.095,
            "revenue_cagr_3y": 0.22,
            "terminal_multiple": 35,
            "ebit_margin_target": 0.2
          },
          "key_drivers": [
            {
              "driver": "Omnipod 5 adoption",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Type 2 market penetration",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "International rollout",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "GLP-1 drug sentiment",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Competitive pricing",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Pharmacy channel expansion",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "R&D pipeline",
              "impact": "LOW",
              "direction": "POS"
            }
          ],
          "method_notes": "Valuation based on 10-year DCF and forward EV/EBITDA. Recommendation reflects 15% upside. Not investment advice.",
          "current_price": 203.51,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Omnipod 5 is the only tubeless AID system, offering a unique competitive advantage.",
            "Massive untapped market in Type 2 diabetes patients currently using MDI therapy.",
            "GLP-1 impact is likely overstated; data shows increased pump adoption among users.",
            "Strong gross margins provide significant operating leverage as the business scales.",
            "International expansion and pharmacy channel access drive sustainable 20%+ revenue growth."
          ],
          "target_price_6m": 218,
          "target_price_12m": 235
        },
        "errorsJson": {
          "attempts": [
            {
              "error": "not_json_object: Output must be a single JSON object (no markdown/code fences, no extra text).",
              "attempt": 0,
              "rawOutputTruncated": "{\"model\":\"Equity Research Analyst Model\",\"as_of\":\"2026-04-08T20:00:01.000Z\",\"ticker\":\"PODD\",\"currency\":\"USD\",\"current_price\":203.51,\"target_price_6m\":220.0,\"target_price_12m\":240.0,\"recommendation\":\"BUY\",\"confidence\":0.7,\"thesis_bullets\":[\"Omnipod 5 remains the only tubeless AID system, providing a unique competitive advantage.\",\"Massive untapped market in Type 2 diabetes patients currently using MDI therapy.\",\"GLP-1 impact is likely overstated; data shows increased pump adoption among GLP-1 users.\",\"Strong gross margins provide significant operating leverage as the business scales.\",\"International expansion and pharmacy channel access drive sustainable 20%+ revenue growth.\"],\"key_drivers\":[{\"driver\":\"Omnipod 5 adoption\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Type 2 market penetration\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"International rollout\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"GLP-1 drug sentiment\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Competitive pricing\",\"impact\":\"MED\",\"direction\":\""
            },
            {
              "error": "not_json_object: Output must be a single JSON object (no markdown/code fences, no extra text).",
              "attempt": 1,
              "rawOutputTruncated": "{\"model\":\"Equity Research Analyst Model\",\"as_of\":\"2026-04-08T20:00:01.000Z\",\"ticker\":\"PODD\",\"currency\":\"USD\",\"current_price\":203.51,\"target_price_6m\":218.0,\"target_price_12m\":235.0,\"recommendation\":\"BUY\",\"confidence\":0.65,\"thesis_bullets\":[\"Omnipod 5 remains the only tubeless AID system, providing a unique competitive advantage.\",\"Massive untapped market in Type 2 diabetes patients currently using MDI therapy.\",\"GLP-1 impact is likely overstated; data shows increased pump adoption among users.\",\"Strong gross margins provide significant operating leverage as the business scales.\",\"International expansion and pharmacy channel access drive sustainable 20%+ revenue growth.\"],\"key_drivers\":[{\"driver\":\"Omnipod 5 adoption\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Type 2 market penetration\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"International rollout\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"GLP-1 drug sentiment\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Competitive pricing\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\""
            }
          ],
          "providerMeta": {
            "model": "gemini-3-flash-preview",
            "provider": "gemini",
            "webSearch": {
              "used": false,
              "allowed": false,
              "enabled": false,
              "requested": false,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 30940,
        "createdAt": "2026-04-09T05:21:36.922Z",
        "usage": {
          "inputTokens": 2690,
          "outputTokens": 525,
          "costUsd": 0.01168
        }
      },
      {
        "id": "cmnr14uxr05tdp658eb314mlo",
        "runId": "cmnr14uxp05tcp658778h4dms",
        "modelId": "openai.gpt-5.4",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T20:00:01.000Z\",\"ticker\":\"PODD\",\"currency\":\"USD\",\"current_price\":203.51,\"target_price_6m\":212,\"target_price_12m\":220,\"recommendation\":\"BUY\",\"confidence\":0.61,\"thesis_bullets\":[\"Omnipod adoption and international expansion keep revenue growth above medtech peers.\",\"High gross margin supports operating leverage as automated insulin delivery scales.\",\"Cash generation is improving, though TTM free cash flow remains slightly negative.\",\"Valuation has compressed materially from highs, but still embeds premium execution expectations.\",\"Mixed setup supports only modest upside unless margin expansion reaccelerates.\"],\"key_drivers\":[{\"driver\":\"Omnipod 5 patient adds\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"U.S. pharmacy channel penetration\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"International rollout\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Type 2 diabetes expansion\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Gross margin expansion\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Sales and R&D discipline\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Reimbursement or formulary pressure\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Pump and AID competition\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Manufacturing reliability\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Slower Omnipod 5 adoption or patient churn.\",\"Reimbursement or formulary pressure from major payors.\",\"Manufacturing or supply disruptions.\",\"Competitive responses from Medtronic, Tandem, or new entrants.\",\"Premium multiple remains vulnerable to earnings misses.\"],\"assumptions\":{\"revenue_cagr_3y\":17.5,\"ebit_margin_target\":21.5,\"wacc\":8.8,\"terminal_multiple\":7.2},\"scenarios\":{\"bear\":{\"target_price\":170,\"prob\":0.25,\"notes\":\"Adoption slows and the multiple compresses after softer execution.\"},\"base\":{\"target_price\":220,\"prob\":0.5,\"notes\":\"Steady pod growth and modest margin expansion support limited rerating.\"},\"bull\":{\"target_price\":265,\"prob\":0.25,\"notes\":\"Faster international and type 2 uptake drives stronger operating leverage.\"}},\"method_notes\":\"Targets use a blended forward EV/sales and margin-normalized framework anchored to snapshot fundamentals; no sell-side price targets used. Snapshot market cap and shares outstanding appear inconsistent with price, so I relied on quote fields plus EV/revenue context. Modest 12M upside supports BUY; not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:01.000Z",
          "model": "OpenAI o3",
          "risks": [
            "Slower Omnipod 5 adoption or patient churn.",
            "Reimbursement or formulary pressure from major payors.",
            "Manufacturing or supply disruptions.",
            "Competitive responses from Medtronic, Tandem, or new entrants.",
            "Premium multiple remains vulnerable to earnings misses."
          ],
          "ticker": "PODD",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Steady pod growth and modest margin expansion support limited rerating.",
              "target_price": 220
            },
            "bear": {
              "prob": 0.25,
              "notes": "Adoption slows and the multiple compresses after softer execution.",
              "target_price": 170
            },
            "bull": {
              "prob": 0.25,
              "notes": "Faster international and type 2 uptake drives stronger operating leverage.",
              "target_price": 265
            }
          },
          "confidence": 0.61,
          "assumptions": {
            "wacc": 8.8,
            "revenue_cagr_3y": 17.5,
            "terminal_multiple": 7.2,
            "ebit_margin_target": 21.5
          },
          "key_drivers": [
            {
              "driver": "Omnipod 5 patient adds",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "U.S. pharmacy channel penetration",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "International rollout",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Type 2 diabetes expansion",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Gross margin expansion",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Sales and R&D discipline",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Reimbursement or formulary pressure",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Pump and AID competition",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Manufacturing reliability",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Targets use a blended forward EV/sales and margin-normalized framework anchored to snapshot fundamentals; no sell-side price targets used. Snapshot market cap and shares outstanding appear inconsistent with price, so I relied on quote fields plus EV/revenue context. Modest 12M upside supports BUY; not investment advice.",
          "current_price": 203.51,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Omnipod adoption and international expansion keep revenue growth above medtech peers.",
            "High gross margin supports operating leverage as automated insulin delivery scales.",
            "Cash generation is improving, though TTM free cash flow remains slightly negative.",
            "Valuation has compressed materially from highs, but still embeds premium execution expectations.",
            "Mixed setup supports only modest upside unless margin expansion reaccelerates."
          ],
          "target_price_6m": 212,
          "target_price_12m": 220
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "openai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "resp_02d39f8645c3b6290069d75c91f4dc8190ae71d5dd1a4df796",
            "reasoningEffort": "medium",
            "structuredOutputs": {
              "used": true,
              "requested": true,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 59833,
        "createdAt": "2026-04-09T05:21:36.922Z",
        "usage": {
          "inputTokens": 2288,
          "outputTokens": 3001,
          "costUsd": 0.046018
        }
      },
      {
        "id": "cmnr14uxr05tgp6588u90xvd6",
        "runId": "cmnr14uxp05tcp658778h4dms",
        "modelId": "xai.grok-4.20-reasoning",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"AI-Driven DCF Model\",\n  \"as_of\": \"2026-04-08T20:00:01.000Z\",\n  \"ticker\": \"PODD\",\n  \"currency\": \"USD\",\n  \"current_price\": 203.51,\n  \"target_price_6m\": 222,\n  \"target_price_12m\": 240,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.62,\n  \"thesis_bullets\": [\n    \"Strong 31% revenue growth via Omnipod 5 adoption\",\n    \"70%+ gross margins support operating leverage\",\n    \"International expansion offers major growth runway\",\n    \"Competition and negative FCF remain key concerns\",\n    \"Rich 210x forward PE demands flawless execution\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Omnipod 5 adoption rates\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"International market penetration\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Diabetes tech innovation\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Competitive intensity\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"EBIT margin expansion\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Reimbursement and regulation\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Free cash flow trajectory\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Overall healthcare spending\",\n      \"impact\": \"LOW\",\n      \"direction\": \"POS\"\n    }\n  ],\n  \"risks\": [\n    \"Intensifying competition from Medtronic/Tandem\",\n    \"Delayed international regulatory approvals\",\n    \"Persistent negative free cash flow\",\n    \"Potential reimbursement cuts\",\n    \"Product recalls or quality issues\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.22,\n    \"ebit_margin_target\": 0.24,\n    \"wacc\": 0.09,\n    \"terminal_multiple\": 32\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 165,\n      \"prob\": 0.3,\n      \"notes\": \"Slower adoption and margin pressure from competition.\"\n    },\n    \"base\": {\n      \"target_price\": 240,\n      \"prob\": 0.5,\n      \"notes\": \"Steady 22% growth and margin improvement on plan.\"\n    },\n    \"bull\": {\n      \"target_price\": 305,\n      \"prob\": 0.2,\n      \"notes\": \"Accelerated global uptake and superior execution.\"\n    }\n  },\n  \"method_notes\": \"3-year DCF with revenue CAGR, EBIT target, WACC and terminal EBIT multiple. Base implies ~18% upside. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:01.000Z",
          "model": "AI-Driven DCF Model",
          "risks": [
            "Intensifying competition from Medtronic/Tandem",
            "Delayed international regulatory approvals",
            "Persistent negative free cash flow",
            "Potential reimbursement cuts",
            "Product recalls or quality issues"
          ],
          "ticker": "PODD",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Steady 22% growth and margin improvement on plan.",
              "target_price": 240
            },
            "bear": {
              "prob": 0.3,
              "notes": "Slower adoption and margin pressure from competition.",
              "target_price": 165
            },
            "bull": {
              "prob": 0.2,
              "notes": "Accelerated global uptake and superior execution.",
              "target_price": 305
            }
          },
          "confidence": 0.62,
          "assumptions": {
            "wacc": 0.09,
            "revenue_cagr_3y": 0.22,
            "terminal_multiple": 32,
            "ebit_margin_target": 0.24
          },
          "key_drivers": [
            {
              "driver": "Omnipod 5 adoption rates",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "International market penetration",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Diabetes tech innovation",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Competitive intensity",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "EBIT margin expansion",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Reimbursement and regulation",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Free cash flow trajectory",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Overall healthcare spending",
              "impact": "LOW",
              "direction": "POS"
            }
          ],
          "method_notes": "3-year DCF with revenue CAGR, EBIT target, WACC and terminal EBIT multiple. Base implies ~18% upside. Not investment advice.",
          "current_price": 203.51,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Strong 31% revenue growth via Omnipod 5 adoption",
            "70%+ gross margins support operating leverage",
            "International expansion offers major growth runway",
            "Competition and negative FCF remain key concerns",
            "Rich 210x forward PE demands flawless execution"
          ],
          "target_price_6m": 222,
          "target_price_12m": 240
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "xai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "769c49b0-0aaa-974e-98d8-e4abab0db4c0",
            "usedFallbackChatCompletions": false
          },
          "sanityIssues": []
        },
        "latencyMs": 15922,
        "createdAt": "2026-04-09T05:21:36.922Z",
        "usage": {
          "inputTokens": 2626,
          "outputTokens": 2818,
          "costUsd": 0.050148
        }
      }
    ]
  }
}